Molecular profiling of Bladder Cancer to support personalized medicine

Publications

Peer reviewed articles (6)

Proteomics biomarkers for solid tumors: Current status and future prospects

Author(s): Iwona Belczacka, Agnieszka Latosinska, Jochen Metzger, David Marx, Antonia Vlahou, Harald Mischak, Maria Frantzi
Published in: Mass Spectrometry Reviews, Issue 38/1, 2017, Page(s) 49-78, ISSN 0277-7037
DOI: 10.1002/mas.21572

Clinical Proteomics on the Path Toward Implementation: First Promises Delivered

Author(s): Maria Frantzi, Harald Mischak, Agnieszka Latosinska
Published in: PROTEOMICS – Clinical Applications, Issue 13/2, 2019, Page(s) 1800094, ISSN 1862-8346
DOI: 10.1002/prca.201800094

Urinary peptide panel for prognostic assessment of bladder cancer relapse

Author(s): Magdalena Krochmal, Kim E. M. van Kessel, Ellen C. Zwarthoff, Iwona Belczacka, Martin Pejchinovski, Antonia Vlahou, Harald Mischak, Maria Frantzi
Published in: Scientific Reports, Issue 9/1, 2019, ISSN 2045-2322
DOI: 10.1038/s41598-019-44129-y

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Author(s): Agnieszka Latosinska, Maria Frantzi, Antonia Vlahou, Axel S. Merseburger, Harald Mischak
Published in: PROTEOMICS - Clinical Applications, Issue 12/2, 2018, Page(s) 1700074, ISSN 1862-8346
DOI: 10.1002/prca.201700074

Promise and Implementation of Proteomic Prostate Cancer Biomarkers

Author(s): Agnieszka Latosinska, Maria Frantzi, Axel S. Merseburger, Harald Mischak
Published in: Diagnostics, Issue 8/3, 2018, Page(s) 57, ISSN 2075-4418
DOI: 10.3390/diagnostics8030057

Clinical Proteomics: Closing the Gap from Discovery to Implementation

Author(s): Maria Frantzi, Agnieszka Latosinska, Georgia Kontostathi, Harald Mischak
Published in: PROTEOMICS, Issue 18/14, 2018, Page(s) 1700463, ISSN 1615-9853
DOI: 10.1002/pmic.201700463